Kineta Announces Restructuring and Exploration of Strategic Alternatives
SEATTLE, Feb. 29, 2024 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...